SuperworthArcturus Therapeutics EPS ARCT
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$3.31
- Latest quarter, Q2 FY26
- −$0.84
- Fiscal year 2025
- −$2.38
Arcturus Therapeutics' earnings per share was −$3.31 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.84.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.38 | n/a |
| FY2024 | −$3.01 | n/a |
| FY2023 | −$1.16 | −604% |
| FY2022 | $0.23 | n/a |
| FY2021 | −$7.74 | n/a |
| FY2020 | −$3.39 | n/a |
| FY2019 | −$2.07 | n/a |
| FY2018 | −$2.17 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.84 | n/a | −$3.31 | |
| Q1 FY26 | −$0.95 | n/a | −$2.81 | |
| Q4 FY25 | −$1.03 | n/a | −$2.38 | |
| Q3 FY25 | −$0.49 | n/a | −$2.46 | |
| Q2 FY25 | −$0.34 | n/a | −$2.23 | |
| Q1 FY25 | −$0.52 | n/a | −$2.53 | |
| Q4 FY24 | −$1.11 | n/a | −$3.01 | |
| Q3 FY24 | −$0.26 | n/a | −$2.34 | |
| Q2 FY24 | −$0.64 | n/a | −$2.69 | |
| Q1 FY24 | −$1.00 | −153% | −$4.03 | |
| Q4 FY23 | −$0.44 | −110% | −$1.16 | |
| Q3 FY23 | −$0.61 | n/a | $3.60 |
Against its peers
Companies in Drug Manufacturers - General nearest Arcturus Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ARCTArcturus Therapeutics | −$3.31 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| LFVNLifevantage | $0.40 | −46% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| Peer median | $0.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Arcturus Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.